TY - JOUR
T1 - Impact of pulsed electromagnetic field therapy on vascular function and blood pressure in hypertensive individuals
AU - Stewart, Glenn M.
AU - Wheatley-Guy, Courtney M.
AU - Johnson, Bruce D.
AU - Shen, Win K.
AU - Kim, Chul Ho
N1 - Publisher Copyright:
© 2020 Wiley Periodicals, Inc.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - The present study investigated the impact of 12 weeks of pulsed electromagnetic field (PEMF) therapy on peripheral vascular function, blood pressure (BP), and nitric oxide in hypertensive individuals. Thirty hypertensive individuals (SBP > 130 mm Hg and/or MAP > 100 mm Hg) were assigned to either PEMF group (n = 15) or control group (n = 15). During pre-assessment, participants underwent measures of flow-mediated dilation (FMD), BP, and blood draw for nitric oxide (NO). Subsequently, they received PEMF therapy 3x/day for 12 weeks and, at conclusion, returned to the laboratory for post-assessment. Fifteen participants from the PEMF group and 11 participants from the control group successfully completed the study protocol. After therapy, the PEMF group demonstrated significant improvements in FMD and FMDNOR (normalized to hyperemia), but the control group did not (P =.05 and P =.04, respectively). Moreover, SBP, DBP, and MAP were reduced, but the control group did not (P =.04,.04, and.03, respectively). There were no significant alterations in NO in both groups (P >.05). Twelve weeks of PEMF therapy may improve BP and vascular function in hypertensive individuals. Additional studies are needed to identify the mechanisms by which PEMF affects endothelial function.
AB - The present study investigated the impact of 12 weeks of pulsed electromagnetic field (PEMF) therapy on peripheral vascular function, blood pressure (BP), and nitric oxide in hypertensive individuals. Thirty hypertensive individuals (SBP > 130 mm Hg and/or MAP > 100 mm Hg) were assigned to either PEMF group (n = 15) or control group (n = 15). During pre-assessment, participants underwent measures of flow-mediated dilation (FMD), BP, and blood draw for nitric oxide (NO). Subsequently, they received PEMF therapy 3x/day for 12 weeks and, at conclusion, returned to the laboratory for post-assessment. Fifteen participants from the PEMF group and 11 participants from the control group successfully completed the study protocol. After therapy, the PEMF group demonstrated significant improvements in FMD and FMDNOR (normalized to hyperemia), but the control group did not (P =.05 and P =.04, respectively). Moreover, SBP, DBP, and MAP were reduced, but the control group did not (P =.04,.04, and.03, respectively). There were no significant alterations in NO in both groups (P >.05). Twelve weeks of PEMF therapy may improve BP and vascular function in hypertensive individuals. Additional studies are needed to identify the mechanisms by which PEMF affects endothelial function.
KW - anti-hypertensive therapy
KW - hypertension
KW - nitric oxide
KW - vascular function
UR - http://www.scopus.com/inward/record.url?scp=85084421987&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084421987&partnerID=8YFLogxK
U2 - 10.1111/jch.13877
DO - 10.1111/jch.13877
M3 - Article
C2 - 32401418
AN - SCOPUS:85084421987
SN - 1524-6175
VL - 22
SP - 1083
EP - 1089
JO - Journal of Clinical Hypertension
JF - Journal of Clinical Hypertension
IS - 6
ER -